Abstract
Development of an effective preventive or therapeutic vaccine against HIV-1 is an important goal in the fight against AIDS. Effective virus clearance and inhibition of spread to target organs depends principally on the cellular immune response. Therefore, a vaccine against HIV-1 should elicit virus-specific cytotoxic lymphocyte (CTL) responses to eliminate the virus during the cell-associated stages of its life cycle. The vaccine should also be capable of inducing immunity at the mucosal surfaces, the primary route of transmission. Recombinant Bacille Calmette-Guerin (BCG) expressing viral proteins offers an excellent candidate vaccine in view of its safety and ability to persist intracellularly, resulting in the induction of long-lasting immunity and stimulation of the cellular immune response. BCG can be administered orally to induce HIV-specific immunity at the mucosal surfaces. The immunogenicity of four recombinant BCG constructs expressing simian immunodeficiency virus (SIV) Gag, Pol, Env, and Nef proteins was tested in rhesus macaques. A single simultaneous inoculation of all four recombinants elicited SIV-specific IgA and IgG antibody, and cellular immune responses, including CTL and helper T cell proliferation. Our results demonstrate that BCG recombinant vectors can induce concomitant humoral and cellular immune responses to the major proteins of SIV. (C) 2000 Academic Press.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 94-103 |
| Number of pages | 10 |
| Journal | Virology |
| Volume | 268 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 1 2000 |
Fingerprint
ASJC Scopus subject areas
- Virology
- Infectious Diseases
Cite this
The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins. / Leung, Nancy J.; Aldovini, Anna; Young, Richard; Jarvis, Michael A.; Smith, James M.; Meyer, Debra; Anderson, David E.; Carlos, Maria P.; Gardner, Murray B.; Torres, Jose V.
In: Virology, Vol. 268, No. 1, 01.03.2000, p. 94-103.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins
AU - Leung, Nancy J.
AU - Aldovini, Anna
AU - Young, Richard
AU - Jarvis, Michael A.
AU - Smith, James M.
AU - Meyer, Debra
AU - Anderson, David E.
AU - Carlos, Maria P.
AU - Gardner, Murray B.
AU - Torres, Jose V
PY - 2000/3/1
Y1 - 2000/3/1
N2 - Development of an effective preventive or therapeutic vaccine against HIV-1 is an important goal in the fight against AIDS. Effective virus clearance and inhibition of spread to target organs depends principally on the cellular immune response. Therefore, a vaccine against HIV-1 should elicit virus-specific cytotoxic lymphocyte (CTL) responses to eliminate the virus during the cell-associated stages of its life cycle. The vaccine should also be capable of inducing immunity at the mucosal surfaces, the primary route of transmission. Recombinant Bacille Calmette-Guerin (BCG) expressing viral proteins offers an excellent candidate vaccine in view of its safety and ability to persist intracellularly, resulting in the induction of long-lasting immunity and stimulation of the cellular immune response. BCG can be administered orally to induce HIV-specific immunity at the mucosal surfaces. The immunogenicity of four recombinant BCG constructs expressing simian immunodeficiency virus (SIV) Gag, Pol, Env, and Nef proteins was tested in rhesus macaques. A single simultaneous inoculation of all four recombinants elicited SIV-specific IgA and IgG antibody, and cellular immune responses, including CTL and helper T cell proliferation. Our results demonstrate that BCG recombinant vectors can induce concomitant humoral and cellular immune responses to the major proteins of SIV. (C) 2000 Academic Press.
AB - Development of an effective preventive or therapeutic vaccine against HIV-1 is an important goal in the fight against AIDS. Effective virus clearance and inhibition of spread to target organs depends principally on the cellular immune response. Therefore, a vaccine against HIV-1 should elicit virus-specific cytotoxic lymphocyte (CTL) responses to eliminate the virus during the cell-associated stages of its life cycle. The vaccine should also be capable of inducing immunity at the mucosal surfaces, the primary route of transmission. Recombinant Bacille Calmette-Guerin (BCG) expressing viral proteins offers an excellent candidate vaccine in view of its safety and ability to persist intracellularly, resulting in the induction of long-lasting immunity and stimulation of the cellular immune response. BCG can be administered orally to induce HIV-specific immunity at the mucosal surfaces. The immunogenicity of four recombinant BCG constructs expressing simian immunodeficiency virus (SIV) Gag, Pol, Env, and Nef proteins was tested in rhesus macaques. A single simultaneous inoculation of all four recombinants elicited SIV-specific IgA and IgG antibody, and cellular immune responses, including CTL and helper T cell proliferation. Our results demonstrate that BCG recombinant vectors can induce concomitant humoral and cellular immune responses to the major proteins of SIV. (C) 2000 Academic Press.
UR - http://www.scopus.com/inward/record.url?scp=18244423060&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=18244423060&partnerID=8YFLogxK
U2 - 10.1006/viro.1999.0131
DO - 10.1006/viro.1999.0131
M3 - Article
C2 - 10683331
AN - SCOPUS:18244423060
VL - 268
SP - 94
EP - 103
JO - Virology
JF - Virology
SN - 0042-6822
IS - 1
ER -